文献速递妇科肿瘤

Prexasertib在BRCA野生型复发性高级别浆液性卵巢癌中的II期研究

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
PubMed 文献 · Lancet Oncol · 2018-01-18

这项单中心、两阶段、概念验证II期研究纳入28例BRCA野生型复发性高级别浆液性卵巢癌患者,接受prexasertib 105 mg/m2每14天静脉给药。可评估患者中33%达到部分缓解,意向治疗人群为29%;常见3-4级不良事件为中性粒细胞减少(93%)。结论认为该药在此类患者中有临床活性且可耐受。

要点

  • BRCA野生型复发性高级别浆液性卵巢癌中,prexasertib单药客观缓解率33%(可评估人群)。
  • 主要毒性为骨髓抑制,3-4级中性粒细胞减少发生率93%,但多为短暂且可恢复。
  • 研究者认为该药值得在此类患者中进一步开发,尤其铂耐药/难治人群。

核心结论

  • Prexasertib在BRCA野生型高级别浆液性卵巢癌患者中显示出临床活性且可耐受。
  • 该药值得在此类患者中进一步开发,尤其是铂耐药或铂难治患者。

研究设计与样本

  • 开放标签、单中心、两阶段、概念验证II期研究,纳入28例可测量复发性高级别浆液性或高级别子宫内膜样卵巢癌女性。
  • 患者接受prexasertib 105 mg/m2静脉输注1小时,每14天一次,28天为一周期,直至疾病进展、不可耐受毒性或撤回知情同意。
  • 主要终点为研究者根据RECIST 1.1评估的肿瘤缓解,按方案可评估人群和意向治疗人群分析。

主要发现

  • 22例(79%)为铂耐药或铂难治疾病;4例(14%)不可评估RECIST缓解。
  • 按方案可评估的24例中,8例(33%,95%CI 16-55)达到部分缓解;意向治疗人群28例中,8例(29%,95%CI 13-49)达到部分缓解。
  • 常见3-4级治疗中出现的不良事件:中性粒细胞减少26例(93%)、白细胞计数降低23例(82%)、血小板减少7例(25%)、贫血3例(11%)。
  • 首次给药后4级中性粒细胞减少22例(79%),中位持续时间6天(IQR 4-8),均未用生长因子支持自行恢复;3级发热性中性粒细胞减少2例(7%)。

临床怎么用

  • 对于BRCA野生型复发性高级别浆液性卵巢癌,尤其是铂耐药或铂难治患者,prexasertib单药显示出一定抗肿瘤活性。
  • 治疗期间需密切监测血常规,重点关注中性粒细胞减少及发热性中性粒细胞减少。

局限性

  • 单中心、小样本II期研究,结果需更大规模研究验证。
  • 4例(14%)患者不可评估RECIST缓解。
  • 研究期间1例患者因肿瘤进展死亡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-grade serous ovarian carcinoma is characterised by TP53 mutations, DNA repair defects, and genomic instability. We hypothesised that prexasertib (LY2606368), a cell cycle checkpoint kinase 1 and 2 inhibitor, would be active in BRCA wild-type disease. METHODS: In an open-label, single-centre, two-stage, proof-of-concept phase 2 study, we enrolled women aged 18 years or older with measurable, recurrent high-grade serous or high-grade endometrioid ovarian carcinoma. All patients had a negative family history of hereditary breast and ovarian cancer or known BRCA wild-type status, measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status score 0-2, and adequate haematological, renal, hepatic, and bone-marrow function. Patients received intravenous prexasertib 105 mg/m2 administered over 1 h every 14 days in 28-day cycles until disease progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint of investigator-assessed tumour response, based on RECIST version 1.1, was assessed per protocol (assessable patients who had undergone CT imaging at baseline and attended at least one protocol-specified follow-up) and by intention to treat. The final analysis of this cohort of patients with BRCA wild-type high-grade serous ovarian carcinoma is reported here. This ongoing trial is registered with ClinicalTrials.gov, number NCT02203513, and continues to enrol patients for the BRCA-mutated ovarian cancer cohort. FINDINGS: Between Jan 20, 2015, and Nov 2, 2016, we enrolled 28 women with a median age of 64 years (IQR 58·0-69·5) who had previously received a median of 5·0 (IQR 2·5-5·0) systemic therapies. Most patients (22 [79%]) had platinum-resistant or platinum-refractory disease. All women received at least one dose of prexasertib, but four (14%) of 28 patients were not assessable for RECIST response. Eight (33%, 95% CI 16-55) of 24 patients assessable per protocol had partial responses. In the intention-to-treat population, eight (29%, 95% CI 13-49) of 28 had a partial responses. The most common (in >10% patients) grade 3 or 4 treatment-emergent adverse events were neutropenia in 26 (93%) of 28 patients, reduced white blood cell count in 23 (82%), thrombocytopenia in seven (25%), and anaemia in three (11%). Grade 4 neutropenia was reported in 22 (79%) patients after the first dose of prexasertib and was transient (median duration 6 days [IQR 4-8]) and recovered without growth-factor support in all cases. The treatment-related serious adverse event of grade 3 febrile neutropenia was reported in two (7%) patients. One patient died during the study due to tumour progression. INTERPRETATION: Prexasertib showed clinical activity and was tolerable in patients with BRCA wild-type high-grade serous ovarian carcinoma. This drug warrants further development in this setting, especially for patients with platinum-resistant or platinum-refractory disease. FUNDING: Intramural Research Program of the National Institutes of Health and National Cancer Institute.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Lee JM, Nair J, Zimmer A, et al. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. Lancet Oncol. 2018. PMID: 29361470. doi:10.1016/S1470-2045(18)30009-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。